2. Search Result
Search Result
Results for "

Talazoparib

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16106
    Talazoparib
    70+ Cited Publications

    BMN-673; LT-673

    		 PARP Cancer
    Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .
    Talazoparib
  • HY-108413
    Talazoparib tosylate
    70+ Cited Publications

    BMN 673ts

    		 PARP Cancer
    Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC50 of 0.57 nM for PARP1.
    Talazoparib tosylate
  • HY-16106A
    (8R,9S)-Talazoparib

    (8R,9S)-BMN-673; (8R,9S)-LT-673

    		 PARP Cancer
    (8R,9S)-Talazoparib ((8R,9S)-BMN-673) is an enantiomer of Talazoparib. (8R,9S)-Talazoparib is an PARP1 inhibitor, with an IC50 of 144 nM .
    (8R,9S)-Talazoparib
  • HY-155993
    YCH1899

    		PARP Cancer
    YCH1899 is an orally active PARP inhibitor, with an IC50< 0.001 nM for PARP1/2. YCH1899 exhibits distinct antiproliferation activity against Olaparib (HY-10162)-resistant and Talazoparib (HY-16106)-resistant Capan-1 cells (Capan-1/OP and Capan-1/TP cells) , with IC50 values of 0.89 and 1.13 nM, respectively. YCH1899 has acceptable pharmacokinetic properties in rats .
    YCH1899
  • HY-16106S
    Talazoparib-13C,d4

    BMN-673-13C,d4; LT-673-13C,d4

    		 Isotope-Labeled Compounds Others
    Talazoparib- 13C,d4 is 13C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.
    Talazoparib-13C,d4
  • HY-14687
    (rac)-Talazoparib

    (rac)-BMN-673; (rac)-LT-673

    		 PARP Cancer
    (rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is the orally active inhibitor for PARP1/2 with Ki of 1.2 nM and 0.87 nM. (rac)-Talazoparib inhibits cellular PARylation with an EC50 of 2.51 nM. (rac)-Talazoparib causes the accumulation of DNA damage, inhibits proliferation of BRCA1/2-mutated MX-1 cell and Capan-1 cell with IC50 of 0.3 nM and 5 nM. (rac)-Talazoparib exhibits antitumor efficacy in mouse models .
    (rac)-Talazoparib
  • HY-172252
    CSN5-IN-2

    		PD-1/PD-L1 RAD51 Cancer
    CSN5-IN-2 (Compound 31) is a CSN5 inhibitor with an IC50 of 0.36 μM. CSN5-IN-2 can increase the level of Cullin 1 neddylation, and downregulate the expression of RAD51 and PD-L1 in cancer cells. CSN5-IN-2 has anti-tumor activity, and its effect is better when combined with Talazoparib (HY-16106) .
    CSN5-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: